| Year |
Title |
Altmetric |
| 2018
|
Identification of Cosalane as an Inhibitor of Human and Murine CC–Chemokine Receptor 7 Signaling via a High-Throughput Screen.
Slas Discovery.
23:1083-1091.
2018
|
|
| 2018
|
Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Cancer Letters.
434:11-21.
2018
|
|
| 2018
|
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.
Collagen and related research.
68-69:28-43.
2018
|
|
| 2018
|
Retraction notice to “SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells” [Canc. Lett. 389C (2017) 41–48] (S030438351630800X) (10.1016/j.canlet.2016.12.030)).
Cancer Letters.
422:131.
2018
|
|
| 2018
|
Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancer.
International Journal of Molecular Sciences.
19.
2018
|
|
| 2018
|
Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.
Nucleic Acids Research.
46:1601-1613.
2018
|
|
| 2017
|
Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signature.
Oncology Reports.
38:2814-2824.
2017
|
|
| 2017
|
SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
Cancer Letters.
389:41-48.
2017
|
|
| 2017
|
Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer"..
Journal of Medicinal Chemistry.
60:7615.
2017
|
|
| 2017
|
Development of a radiosensitivity gene signature for patients with soft tissue sarcoma.
Oncotarget.
8:27428-27439.
2017
|
|
| 2017
|
Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain.
Oncotarget.
8:91459-91470.
2017
|
|
| 2017
|
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Oncotarget.
8:37568-37583.
2017
|
|
| 2016
|
Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells.
Journal of Biological Chemistry.
291:24188-24199.
2016
|
|
| 2016
|
Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations.
American Journal of Respiratory and Critical Care Medicine.
194:1092-1103.
2016
|
|
| 2016
|
Discovery of a novel inhibitor of kinesin-like protein KIFC1.
Biochemical Journal.
473:1027-1035.
2016
|
|
| 2016
|
Consortia's critical role in developing medical countermeasures for re-emerging viral infections: A USA perspective.
Future Virology.
11:187-195.
2016
|
|
| 2016
|
Inhibition of transforming growth factor-β activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma.
American Journal of Pathology.
186:678-690.
2016
|
|
| 2015
|
High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.
Nucleic Acids Research.
43:1987-1996.
2015
|
|
| 2014
|
Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
Journal of Biological Chemistry.
289:32937-32951.
2014
|
|
| 2014
|
AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (bret) assays for identification of Tau-Fyn sh3 interaction inhibitors for Alzheimer disease.
Journal of Biomolecular Screening.
19:1338-1349.
2014
|
|
| 2013
|
Role of Adiponectin in the metabolic syndrome: Current perspectives on its modulation as a treatment strategy.
Current Pharmaceutical Design.
19:5755-5763.
2013
|
|
| 2012
|
3D Cell Cultures. Mimicking In Vivo Tissues for Improved Predictability in Drug Discovery.
Annual Reports in Medicinal Chemistry.
47:367-378.
2012
|
|
| 2012
|
Process development and optimization for production of a potassium ion channel blocker, ICA-17043.
Organic Process Research and Development.
16:1385-1392.
2012
|
|
| 2012
|
Frizzled7 as an emerging target for cancer therapy.
Cellular Signalling.
24:846-851.
2012
|
|
| 2012
|
The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer.
Journal of Cellular Biochemistry.
113:13-18.
2012
|
|
| 2011
|
N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy.
ACS Medicinal Chemistry Letters.
2:481-484.
2011
|
|
| 2004
|
Design of a gene family screening library targeting G-protein coupled receptors.
Journal of molecular graphics.
23:15-21.
2004
|
|
| 2004
|
Neuronal nicotinic acetylcholine.
Expert Opinion on Therapeutic Targets.
8:61-64.
2004
|
|
| 2003
|
The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of in vitro and in vivo studies.
Bioorganic and Medicinal Chemistry Letters.
13:4077-4080.
2003
|
|
| 2000
|
Inhibitors of NF-κB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3',5'-bis(trifluoromethyl)-phenyl) carboxamide].
Journal of Medicinal Chemistry.
43:3995-4004.
2000
|
|
| 2000
|
Novel inhibitors of AP-1 and NF-κB mediated gene expression: Structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylate.
Bioorganic and Medicinal Chemistry Letters.
10:1645-1648.
2000
|
|
| 2000
|
Designing chiral libraries for drug discovery.
Drug Discovery Today.
5:364-372.
2000
|
|
| 2000
|
Synthesis and structure-activity relationship studies of conformationally restricted, analogs of 2-chloro-4-trifluoromethylpyrimidine- 5-[N-(3',5'-bis(trifluoromethyl)phenyl)]carboxamide.
Medicinal Chemistry Research.
10:19-29.
2000
|
|
| 1999
|
Developments in solution-phase combinatorial chemistry.
Current Opinion in Drug Discovery and Development.
2:377-384.
1999
|
|
| 1998
|
A novel and T cell specific dual inhibitor of NF-κB and AP-1 suppresses alloreactivity in mice through its antiproliferative effect mediated by inhibition of IL-2 production.
Federation proceedings.
12.
1998
|
|
| 1998
|
2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)carboxamide: A potent inhibitor of NF-κB- and AP- 1-mediated gene expression identified using solution-phase combinatorial chemistry.
Journal of Medicinal Chemistry.
41:413-419.
1998
|
|
| 1998
|
A general and regiospecific synthesis of 5,8-disubstituted α- tetralones.
Synthetic Communications.
28:3491-3502.
1998
|
|
| 1997
|
Novel approaches for the treatment of inflammatory diseases: Inhibitors of NF-κB and AP-1.
Current Pharmaceutical Design.
3:515-528.
1997
|
|
| 1997
|
A novel inhibitor of nuclear factor-κB and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo.
Transplantation Proceedings.
29:1269-1270.
1997
|
|
| 1997
|
Ion-exchange resins for solution phase parallel synthesis of chemical libraries.
Tetrahedron Letters.
38:513-516.
1997
|
|
| 1997
|
Traceless linker: Oxidative activation and displacement of a sulfur-based linker.
Tetrahedron Letters.
38:211-214.
1997
|
|
| 1996
|
SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.
Transplantation Proceedings.
28:3106-3109.
1996
|
|
| 1996
|
Peptide inhibitors of IκB protease: Modification of the C-termini of Z-LLF-CHO.
Bioorganic and Medicinal Chemistry Letters.
6:2925-2930.
1996
|
|
| 1996
|
Use of pentafluorophenyl esters for one-pot protection/activation of amino and thiol carboxylic acids.
Tetrahedron Letters.
37:4915-4918.
1996
|
|
| 1995
|
Synthesis of Boxazomycin B and related analogs.
Tetrahedron Letters.
36:7213-7216.
1995
|
|
| 1994
|
Synthesis and Antibacterial Activity of New Quinolones Containing a 7-[3-(1-Amino-1-Methylethyl)-1-pyrrolidinyl] Moiety. Gram-Positive Agents with Excellent Oral Activity and Low Side-Effect Potential.
Journal of Medicinal Chemistry.
37:733-738.
1994
|
|
| 1994
|
An efficient method for the synthesis of (R)-3-(1-amino-1-methylethyl)pyrrolidines for the antiinfective agent, PD 138312.
Tetrahedron: Asymmetry.
5:1131-1134.
1994
|
|
| 1993
|
Stereoselective Michael additions of nitromethane yielding 3R(1S N-substituted aminoethyl)pyrrolidines.
Tetrahedron Letters.
34:7529-7532.
1993
|
|
| 1993
|
3-Ethenyl, 3-ethynyl, 3-aryl, and 3-cyclopropyl-2,4,6-trifluorobenzoic acids: Useful intermediate in the synthesis of quinolone antibacterials.
Tetrahedron Letters.
34:281-284.
1993
|
|
| 1993
|
High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone / naphthyridone antibacterials.
Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure.
298:227-236.
1993
|
|
| 1993
|
Quinolone Antibacterials Containing the New 7-[3-(1-Aminoethyl)-1-pyrrolidinyl] Side Chain: The Effects of the 1-Aminoethyl Moiety and Its Stereochemical Configurations on Potency and in Vivo Efficacy.
Journal of Medicinal Chemistry.
36:871-882.
1993
|
|
| 1992
|
Development of radioimmunoassays for measurement of the specific bronchodilator procaterol in human urine and plasma.
Journal of Clinical Immunoassay.
15:258-264.
1992
|
|
| 1992
|
Fluoroquinolones: Relationships between Structural Variations, Mammalian Cell Cytotoxicity, and Antimicrobial Activity.
Journal of Medicinal Chemistry.
35:4745-4750.
1992
|
|
| 1992
|
Synthesis of chiral 3-substituted-3-aminomethyl-pyrrolidines and related compounds.
Mathematical Problems in Engineering.
29:1441-1448.
1992
|
|
| 1992
|
The biochemistry and pharmacology of PD 116124 (8-amino-2'- nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Journal of Pharmacology and Experimental Therapeutics.
260:319-326.
1992
|
|
| 1992
|
Antibacterial Agents, Targets and Approaches.
Annual Reports in Medicinal Chemistry.
27:119-128.
1992
|
|
| 1992
|
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908).
International Journal of Radiation Oncology - Biology - Physics.
22:545-548.
1992
|
|
| 1992
|
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
International Journal of Radiation Oncology - Biology - Physics.
22:549-551.
1992
|
|
| 1992
|
Synthesis of chiral 3‐substituted‐3‐aminomethyl‐pyrrolidines and related compounds.
Journal of Heterocyclic Chemistry.
29:1441-1448.
1992
|
|
| 1991
|
Synthesis and Evaluation of a Series of 3,5-Disubstituted Benzisoxazole-4,7-diones. Potent Radiosensitizers in Vitro.
Journal of Medicinal Chemistry.
34:3290-3294.
1991
|
|
| 1991
|
A New Class of Analogues of the Bifunctional Radiosensitizer α-(1-Aziridinylmethyl)-2-nitro-1ff-imidazole-1-ethanol (RSU 1069): The Cycloalkylaziridines.
Journal of Medicinal Chemistry.
34:2484-2488.
1991
|
|
| 1991
|
Dihydroisoquinolinones: The design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase.
Anticancer Drug Design.
6:107-117.
1991
|
|
| 1991
|
Dual-Function Radiosensitizers. α-[[(2-Bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol and Related Compounds: Preparation via an Aziridine Equivalent.
Journal of Medicinal Chemistry.
34:1207-1209.
1991
|
|
| 1991
|
Chapter 16. Radiosensitizers.
Annual Reports in Medicinal Chemistry.
26:151-160.
1991
|
|
| 1991
|
Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells.
Radiation Research.
126:367-371.
1991
|
|
| 1991
|
Inhibitors of poly(ADP-ribose) polymerase (ADPRP): Potential chemotherapeutic agents.
Drugs of the future.
16:723-739.
1991
|
|
| 1990
|
Synthesis and Evaluation of α-[[(2-Haloethyl)amino]methyl]-2-nitro-1H-imidazole-l-ethanols as Prodrugs of α-[(l-Aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its Analogues Which Are Radiosensitizers and Bioreductively Activated Cytotoxins.
Journal of Medicinal Chemistry.
33:2603-2610.
1990
|
|
| 1988
|
1,4-Dihydropyridine Antagonist Activities at the Calcium Channel: A Quantitative Structure-Activity Relationship Approach.
Journal of Medicinal Chemistry.
31:2103-2107.
1988
|
|
| 1987
|
8-amino-9-substituted guanines: Potent purine nucleoside phosphorylase (PNP) inhibitors.
Agents and actions.
21:253-256.
1987
|
|
| 1987
|
Approaches to the Synthesis of Ring C Transposed Progesterone Analogues. rac -7β,15α-Ethano-11,12-seco-11,19-bisnor-17α-pregn-4-ene-3,20-dione and rac-4,4-Dimethyl-7,7-(ethylenedioxy)-(4aα,4bβ,8aα, 10aβ)-perhydro-3-phenanthrenone.
Journal of Organic Chemistry.
52:2263-2273.
1987
|
|
| 1986
|
Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis, Purine Nucleoside Phosphorylase Inhibition, and T-Cell Cytotoxicity of 2,5-Diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-Diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two Thio Isosteres of 8-Aminoguanine.
Journal of Medicinal Chemistry.
29:1804-1806.
1986
|
|
| 1982
|
Relative Affinity of 17α- and/or 21-Esters and 17α,21-Diesters of Cortisol for a Glucocorticoid Receptor from Rat Thymocytes.
Journal of Medicinal Chemistry.
25:747-749.
1982
|
|
| 1980
|
Effect Of C-21 Substituents on the Elimination of a 17α-Acyloxy Group from 17α-(Acyloxy)-20-Oxo Steroids.
Journal of Organic Chemistry.
45:2012-2013.
1980
|
|
